Literature DB >> 837654

Kinetic model for gentamicin dosing with the use of individual patient parameters.

R J Sawchuk, D E Zaske, R J Cipolle, W A Wargin, R G Strate.   

Abstract

Multiple-infusion dosing regimens for gentamicin were established for 84 patients with the use of individually calculated values of elimination kinetic parameters. Serum level-time data obtained after a single infusion were used to determine the patient's gentamicin half-life (t 1/2) and distribution volume. Patients with serum creatinine (Cr) less than 1.2 mg per 100 ml had t 1/2 (mean, 2.25 hr) and total body clearances (mean, 0.082 L/hr/kg) significantly different from those with Cr greater than or equal to 1.2 mg/100 ml (means, 5.3 and 0.039, respectively). Distribution volumes were not significantly different (means, 0.22 and 0.21 L/kg, respectively). Calculations of dosing intervals and infusion rates, based on each patient's kinetic parameters and desired steady-state peaks and nadirs, assumed a one-compartment model with first-order elimination and 1-hr constant-rate input at fixed intervals. Follow-up steady-state peak and nadir levels were measured in 63 of the regimens. Differences between predicted and measured peak levels averaged --0.05 mug/ml with 60% of the measured values falling within 1 mug/ml of that predicted. Predicted-measured nadir differences averaged --0.62 mug/ml (significantly different from zero) indicating slight bias in the model. Fifty-six percent of these nadirs were within 1 mug/ml of that predicted.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 837654     DOI: 10.1002/cpt1977213362

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  76 in total

1.  Comparison of once-daily versus twice-daily administration of cefdinir against typical bacterial respiratory tract pathogens.

Authors:  G H Ross; L B Hovde; K H Ibrahim; Y H Ibrahim; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 2.  Rate and extent of drug accumulation after multiple dosing revisited.

Authors:  Dion R Brocks; Reza Mehvar
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

3.  Therapeutic drug monitoring of antimicrobials.

Authors:  Jason A Roberts; Ross Norris; David L Paterson; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

Review 4.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

5.  Extended Interval Tobramycin Pharmacokinetics in a Pediatric Patient With Primary Ciliary Dyskinesia Presenting With an Acute Respiratory Exacerbation.

Authors:  Kristi L Higgins; Cady Noda; Jeremy S Stultz
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

Review 6.  Once-daily aminoglycoside administration: new strategies for an old drug.

Authors:  J M Kovarik; I M Hoepelman; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-09       Impact factor: 3.267

7.  Pharmacokinetics of gentamicin in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  S Pancorbo; C Comty
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

8.  Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis.

Authors:  Lisa T Hong; Theodore G Liou; Rishi Deka; Jordan B King; Vanessa Stevens; David C Young
Journal:  Chest       Date:  2018-06-13       Impact factor: 9.410

9.  Changes in MIC alter responses of Pseudomonas aeruginosa to tobramycin exposure.

Authors:  L L Ioannides-Demos; L Liolios; P Wood; W J Spicer; A J McLean
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Identification of Risk Factors for Elevated Neonatal Gentamicin Trough Concentrations.

Authors:  Jeffrey Gonzalez; John Ahern; Elizabeth Noyes; Michele Corriveau; Charles Mercier
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.